Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypes

Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette, MD, et al, at the South Beach Symposium.

The pooled analysis included adults with moderate-to-severe CHE treated with twice-daily delgocitinib cream or vehicle for up to 16 weeks. Patients were categorized by etiologic and morphologic subtypes, including irritant contact dermatitis, allergic contact dermatitis, atopic hand eczema, hyperkeratotic, and vesicular disease.

Across subgroups, delgocitinib treatment was associated with statistically significant improvements in itch, pain, and quality of life compared with vehicle, with separation observed early in treatment and maintained through Week 16. Improvements were consistent across multiple PRO instruments, including itch and pain numerical rating scales and the Dermatology Life Quality Index.

The investigators reported that symptom improvement was observed regardless of CHE subtype, supporting the broad anti-inflammatory activity of pan-JAK inhibition in this heterogeneous condition. Safety findings were consistent with previously reported phase 3 data.

“These improvements were statistically significant with delgocitinib cream versus cream vehicle from early timepoints, demonstrating the rapid efficacy of delgocitinib across subtypes of CHE,” the authors wrote in the poster’s conclusion.